4basebio Expands Genezen Partnership for GMP Synthetic DNA in Viral Vector Manufacturing
- 4basebio and Genezen expanded their collaboration to supply enzymatically produced hpDNA® across Research Use Only, High-Quality, and GMP grades for viral vector and cell/gene therapy applications.
- 4basebio's cell-free synthetic DNA manufacturing reduces bacterial contamination, cuts DNA mass requirements by ~30% in AAV production, and shortens timelines versus traditional plasmid methods.
Operational Impact
Genezen's expanded access to 4basebio's GMP hpDNA® reduces viral vector manufacturing cycle time and input costs, enabling faster clinical progression for cell and gene therapy developers using Genezen's platform.
Source: PharmaSource RSS
Artis BioSolutions Opens Genetic Medicines Center of Excellence in Bilbao
- Artis BioSolutions launched an integrated Genetic Medicines Center of Excellence in Bilbao, Spain, offering synthetic DNA, mRNA drug substance, LNP formulation, and GMP drug product manufacturing under one roof.
- The facility consolidates early development through commercialization capabilities, aiming to reduce technology transfer complexity and accelerate program timelines for genetic medicine partners.
Operational Impact
Artis's Bilbao center adds European GMP drug-product capacity for mRNA and LNP therapies, complementing its Boston site and offering CDMO directors a single-vendor platform spanning synthetic DNA through commercial manufacturing.
Source: Contract Pharma Breaking News RSS